Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic advances in hematology Vol. 13; p. 20406207221103321
Main Authors Frontzek, Fabian, Karsten, Imke, Schmitz, Norbert, Lenz, Georg
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.06.2022
Sage Publications Ltd
SAGE Publishing
Subjects
Chemotherapy
Immunotherapy
Lymphoma
Monoclonal antibodies
Review
Stem cell transplantation
Targeted cancer therapy
Transplants & implants
ADC
DLBCL
targeted therapies
CAR T-cells
bispecific antibodies
ASCT
monoclonal antibodies
Online AccessGet full text
ISSN2040-6207
2040-6215
DOI10.1177/20406207221103321

Cover

Abstract Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients with primary refractory disease or relapse (R/R) after an initial response are still characterized by poor outcome. Until now, transplant-eligible R/R DLBCL patients are treated with intensive salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) which, however, only cures a limited number of patients. It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora of novel agents comprising new monoclonal antibodies, antibody drug conjugates (ADC), bispecific antibodies, and CAR T-cells have emerged and have significantly improved outcome of patients with R/R DLBCL. In this review, we summarize our current knowledge on the usage of novel drugs and approaches for the treatment of patients with R/R DLBCL.
AbstractList Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60-65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients with primary refractory disease or relapse (R/R) after an initial response are still characterized by poor outcome. Until now, transplant-eligible R/R DLBCL patients are treated with intensive salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) which, however, only cures a limited number of patients. It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora of novel agents comprising new monoclonal antibodies, antibody drug conjugates (ADC), bispecific antibodies, and CAR T-cells have emerged and have significantly improved outcome of patients with R/R DLBCL. In this review, we summarize our current knowledge on the usage of novel drugs and approaches for the treatment of patients with R/R DLBCL.Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60-65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients with primary refractory disease or relapse (R/R) after an initial response are still characterized by poor outcome. Until now, transplant-eligible R/R DLBCL patients are treated with intensive salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) which, however, only cures a limited number of patients. It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora of novel agents comprising new monoclonal antibodies, antibody drug conjugates (ADC), bispecific antibodies, and CAR T-cells have emerged and have significantly improved outcome of patients with R/R DLBCL. In this review, we summarize our current knowledge on the usage of novel drugs and approaches for the treatment of patients with R/R DLBCL.
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients with primary refractory disease or relapse (R/R) after an initial response are still characterized by poor outcome. Until now, transplant-eligible R/R DLBCL patients are treated with intensive salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) which, however, only cures a limited number of patients. It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora of novel agents comprising new monoclonal antibodies, antibody drug conjugates (ADC), bispecific antibodies, and CAR T-cells have emerged and have significantly improved outcome of patients with R/R DLBCL. In this review, we summarize our current knowledge on the usage of novel drugs and approaches for the treatment of patients with R/R DLBCL.
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of patients can be cured by chemoimmunotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, patients with primary refractory disease or relapse (R/R) after an initial response are still characterized by poor outcome. Until now, transplant-eligible R/R DLBCL patients are treated with intensive salvage regimens followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) which, however, only cures a limited number of patients. It is most likely that in patients with early relapse after chemoimmunotherapy, chimeric antigen receptor (CAR) T-cells will replace high-dose chemotherapy and ASCT. So far, transplant-ineligible patients have mostly been treated in palliative intent. Recently, a plethora of novel agents comprising new monoclonal antibodies, antibody drug conjugates (ADC), bispecific antibodies, and CAR T-cells have emerged and have significantly improved outcome of patients with R/R DLBCL. In this review, we summarize our current knowledge on the usage of novel drugs and approaches for the treatment of patients with R/R DLBCL.
Author Frontzek, Fabian
Karsten, Imke
Schmitz, Norbert
Lenz, Georg
Author_xml – sequence: 1
  givenname: Fabian
  orcidid: 0000-0003-1705-3638
  surname: Frontzek
  fullname: Frontzek, Fabian
  organization: Department of Medicine A for Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
– sequence: 2
  givenname: Imke
  surname: Karsten
  fullname: Karsten, Imke
  organization: Department of Medicine A for Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
– sequence: 3
  givenname: Norbert
  surname: Schmitz
  fullname: Schmitz, Norbert
  organization: Department of Medicine A for Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany
– sequence: 4
  givenname: Georg
  surname: Lenz
  fullname: Lenz, Georg
  email: Georg.Lenz@ukmuenster.de
  organization: Department of Medicine A for Hematology, Oncology, and Pneumology, University Hospital Münster, 48149 Münster, Germany
BookMark eNp9Uk1v1DAUjFARLaU_gJslLlzS-jOOL0iw4qNSJS5wtp6Tl12vkjjYTtGKP0_SLaAWgS9-ep4Ze8bveXEyhhGL4iWjl4xpfcWppBWnmnPGqBCcPSnO1l5ZcaZOftdUnxYXKe3psmQlhFTPilOhdK24lGfFj80cI46ZhCn7MCYCY0u6Oc8RyYQxTdhkf4uJ-JHkHZIcEfJwR-jIBNkvZSLffd6RiD1MCduriF2EJod4IK3vujkh6SFukbwrG-x70h-GaRcGeFE87aBPeHG_nxdfP7z_svlU3nz-eL15e1M2UphcamWQOQOdlJVRUgMzTgoOrmrRaWE4gqO64UwYyWsFSjjqeAPcdBQ7YOK8uD7qtgH2dop-gHiwAby9a4S4tRCzb3q0WDsuUddQIUrjXM1bZiTIzvBWdhVftN4ctabZDdg2i_0I_QPRhyej39ltuLWGS6HMKvD6XiCGbzOmbAef1lhgxDAny6taUcFqYxboq0fQfZjjuERluVa10rTSqzt9RDUxpLRkbxufYf3M5X7fW0btOi_2r3lZmOwR85eN_3Euj5wEW_zznn8TfgJvgtCX
CitedBy_id crossref_primary_10_1002_hon_70054
crossref_primary_10_51847_hjB1M4gCTU
crossref_primary_10_3390_ijms24021045
crossref_primary_10_1016_S2152_2650_24_00374_4
crossref_primary_10_1182_hematology_2023000430
crossref_primary_10_1111_bjh_19860
crossref_primary_10_1080_13696998_2024_2399435
crossref_primary_10_1016_j_clml_2023_11_005
crossref_primary_10_33590_emjhematol_10301096
crossref_primary_10_1016_j_taap_2024_117103
crossref_primary_10_1002_hon_3168_2
crossref_primary_10_1097_HS9_0000000000000984
crossref_primary_10_17235_reed_2022_9100_2022
crossref_primary_10_3892_or_2024_8746
crossref_primary_10_1080_10428194_2024_2438805
crossref_primary_10_21320_2500_2139_2024_17_1_11_17
crossref_primary_10_1007_s40487_024_00265_8
crossref_primary_10_1007_s11033_022_08104_7
Cites_doi 10.1200/JCO.20.01366
10.3324/haematol.2016.147256
10.1182/blood-2019-123742
10.1146/annurev.immunol.26.021607.090331
10.1016/S2352-3026(19)30026-2
10.1016/j.bbmt.2015.05.010
10.1038/s41586-018-0290-0
10.3324/haematol.2016.153957
10.1200/JCO.2010.30.2596
10.1200/JCO.2010.28.1618
10.1200/JCO.19.00172
10.4161/onci.21335
10.1007/s00262-008-0512-7
10.1016/S1470-2045(12)70481-3
10.1038/nbt.2289
10.1016/j.ebiom.2019.102625
10.1016/S1470-2045(18)30935-5
10.1182/bloodadvances.2018027748
10.1182/blood-2021-147913
10.1016/j.ccr.2013.04.011
10.1182/blood-2003-02-0361
10.1016/S0002-9440(10)63284-1
10.1073/pnas.0804295105
10.1182/blood-2015-06-651380
10.1002/hon.84_2879
10.1056/NEJMoa012914
10.1200/JCO.18.00766
10.1016/S1470-2045(08)70002-0
10.1056/NEJMoa1804980
10.1056/NEJMoa1807315
10.1016/j.bbmt.2019.12.108
10.1097/CCO.0000000000000232
10.1016/S0140-6736(20)32334-5
10.1155/2012/513702
10.1056/NEJMoa2115304
10.1016/j.ccell.2020.03.015
10.1200/JCO.2013.53.9593
10.1111/bjh.14046
10.1200/JCO.2016.71.3024
10.1016/j.ccell.2021.10.006
10.1200/JCO.20.03175
10.1016/S1470-2045(14)70161-5
10.1056/NEJMoa1609783
10.1038/nm.3884
10.1200/JCO.18.02403
10.1016/S0140-6736(20)31366-0
10.1007/s00277-011-1395-9
10.1200/JCO.2017.73.3402
10.1182/blood.2020006578
10.1093/annonc/mdm133
10.1182/bloodadvances.2019000025
10.1056/NEJMe2118899
10.1182/bloodadvances.2020003036
10.1016/S0140-6736(21)00889-8
10.1200/JCO.2012.46.5203
10.1016/S1470-2045(06)70664-7
10.1182/blood.2018891598
10.1038/s41591-018-0016-8
10.1080/10428194.2021.1953016
10.1056/NEJMoa2116133
10.1016/S2352-3026(20)30120-4
10.1002/hon.2858
10.1056/NEJMoa2116596
10.1016/S1470-2045(20)30225-4
10.1158/2159-8290.CD-13-1005
10.1182/blood-2009-02-205500
10.1200/JCO.19.02104
10.1038/nrclinonc.2014.221
10.1016/S1470-2045(11)70235-2
10.1056/NEJMoa011795
10.1016/j.it.2004.12.003
10.1016/S1470-2045(21)00375-2
10.1126/scitranslmed.aaa4802
10.1002/hon.145_2630
10.1038/bmt.2015.286
10.1038/35000501
10.1182/blood-2020-136640
10.3324/haematol.2020.275958
10.1182/blood-2017-10-813493
10.1182/blood-2016-12-758599
10.1200/JCO.2014.55.5714
10.1126/science.271.5250.822
10.1158/1078-0432.CCR-16-2818
10.1056/NEJMoa1707447
10.1200/JCO.2014.59.1586
10.1056/NEJMoa1801445
10.1200/JCO.2016.70.4320
10.1182/blood-2017-03-769620
10.1016/j.ccr.2012.05.024
10.3324/haematol.2013.090597
10.1038/s41375-020-0743-y
10.1182/blood-2010-04-279893
10.1038/nature08638
10.1056/NEJMoa1411087
10.1016/S1470-2045(21)00139-X
10.1182/blood-2018-99-113411
10.1073/pnas.1732008100
ContentType Journal Article
Copyright The Author(s), 2022
The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s), 2022.
The Author(s), 2022 2022 SAGE Publications
Copyright_xml – notice: The Author(s), 2022
– notice: The Author(s), 2022. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s), 2022.
– notice: The Author(s), 2022 2022 SAGE Publications
DBID AFRWT
AAYXX
CITATION
3V.
7RV
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
KB0
M0S
NAPCQ
PHGZM
PHGZT
PIMPY
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1177/20406207221103321
DatabaseName Sage Journals GOLD Open Access 2024
CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni)
Nursing & Allied Health Premium
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: AFRWT
  name: Sage Journals GOLD Open Access 2024
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2040-6215
ExternalDocumentID oai_doaj_org_article_e8b24e78a6ee49bb82d194a4f92d4f62
PMC9243592
10_1177_20406207221103321
10.1177_20406207221103321
GroupedDBID ---
01A
0R~
4.4
53G
54M
5VS
7RV
7X7
8FI
8FJ
AAJQC
AAKDD
AARIX
AASGM
ABAWP
ABJIS
ABQXT
ABRHV
ABUWG
ABVFX
ABXGC
ACARO
ACDXX
ACGFS
ACROE
ADBBV
ADEBD
ADOGD
AERKM
AEUHG
AEWDL
AFCOW
AFKRA
AFKRG
AFRWT
AFUIA
AGNHF
AJUZI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
ARTOV
AUTPY
AYAKG
BAWUL
BCNDV
BDDNI
BENPR
BKEYQ
BKSCU
BPHCQ
BSEHC
BVXVI
CCPQU
DC.
DIK
EBS
EJD
EMOBN
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
GX1
H13
HF~
HMCUK
HYE
HZ~
J8X
K.F
N9A
NAPCQ
O9-
OK1
P.B
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
S01
SAUOL
SCDPB
SCNPE
SFC
UKHRP
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PPXIY
PQEST
PQUKI
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c439t-759e1b9af4469547a19b432ab6deb7392eab07c21394285a53b0b2ca29f0efa13
IEDL.DBID AFRWT
ISSN 2040-6207
IngestDate Wed Aug 27 01:26:27 EDT 2025
Thu Aug 21 14:14:15 EDT 2025
Fri Sep 05 14:15:11 EDT 2025
Sat Jul 26 00:11:15 EDT 2025
Tue Jul 01 05:28:02 EDT 2025
Thu Apr 24 23:08:08 EDT 2025
Tue Jun 17 22:28:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords ADC
DLBCL
targeted therapies
CAR T-cells
bispecific antibodies
ASCT
monoclonal antibodies
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c439t-759e1b9af4469547a19b432ab6deb7392eab07c21394285a53b0b2ca29f0efa13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-1705-3638
OpenAccessLink https://journals.sagepub.com/doi/full/10.1177/20406207221103321?utm_source=summon&utm_medium=discovery-provider
PMID 35785244
PQID 2758570671
PQPubID 4450842
ParticipantIDs doaj_primary_oai_doaj_org_article_e8b24e78a6ee49bb82d194a4f92d4f62
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9243592
proquest_miscellaneous_2685031899
proquest_journals_2758570671
crossref_citationtrail_10_1177_20406207221103321
crossref_primary_10_1177_20406207221103321
sage_journals_10_1177_20406207221103321
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-06-01
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-01
  day: 01
PublicationDecade 2020
PublicationPlace London, England
PublicationPlace_xml – name: London, England
– name: London
– name: Sage UK: London, England
PublicationTitle Therapeutic advances in hematology
PublicationYear 2022
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Dreger, Sureda, Ahn 2019; 3
Neelapu, Locke, Bartlett 2017; 377
Schmitz, Nickelsen, Ziepert 2012; 13
Schuster, Bishop, Tam 2019; 380
Dornan, Bennett, Chen 2009; 114
Lenz, Wright, Emre 2008; 105
Advani, Flinn, Popplewell 2018; 379
Roschewski, Longo, Wilson 2022; 386
Riedell, Walling, Nastoupil 2020; 26
Goy, Ramchandren, Ghosh 2019; 134
Schuster, Tam, Borchmann 2021; 22
Glass, Hasenkamp, Wulf 2014; 15
Davis, Ngo, Lenz 2010; 463
Rigacci, Puccini, Dodero 2012; 91
Bishop, Dickinson, Purtill 2022; 386
Urbano-Ispizua, Pavletic, Flowers 2015; 21
Wright, Huang, Phelan 2020; 37
Crump, Neelapu, Farooq 2017; 130
Rawlings, Scharenberg, Park 1996; 271
Wright, Tan, Rosenwald 2003; 100
Zammarchi, Corbett, Adams 2018; 131
Klebanoff, Khong, Antony 2005; 26
Wilson, Wright, Huang 2021; 39
Schmitz, Wright, Huang 2018; 378
Ansell, Lesokhin, Borrello 2015; 372
Coiffier, Lepage, Briere 2002; 346
Beguelin, Popovic, Teater 2013; 23
Sehn, Herrera, Flowers 2020; 38
Kamdar, Solomon, Arnason 2021; 138
Errico 2015; 12
Dufner, Sayehli, Chatterjee 2019; 3
Rosenwald, Wright, Chan 2002; 346
Minson, Dickinson 2021; 62
Le Gouill, Bachy, Blasi 2021; 39
Hutchings, Morschhauser, Iacoboni 2021; 39
Ansell, Minnema, Johnson 2019; 37
Jacobson, Locke, Ghobadi 2020; 136
Schuster, Bartlett, Assouline 2019; 134
Younes, Sehn, Johnson 2019; 37
Zinzani, Pellegrini, Argnani 2016; 101
Lenz, Hawkes, Verhoef 2020; 34
Dreger, Dietrich, Schubert 2020; 4
Mounier, El Gnaoui, Tilly 2013; 98
Tilly, Morschhauser, Sehn 2022; 386
Duell, Maddocks, Gonzalez-Barca 2021; 106
Godwin, Freytes, Maris 2020 1196; 136
Kalakonda, Maerevoet, Cavallo 2020; 7
Viardot, Goebeler, Hess 2016; 127
Kochenderfer, Somerville, Lu 2017; 35
Pfreundschuh, Kuhnt, Trumper 2011; 12
Gorgun, Calabrese, Soydan 2010; 116
Benjamin, Graham, Yallop 2020; 396
Schuster 2021; 39
Priceman, Forman, Brown 2015; 27
Gisselbrecht, Glass, Mounier 2010; 28
Davies, Cummin, Barrans 2019; 20
Czuczman, Trneny, Davies 2017; 23
Keir, Butte, Freeman 2008; 26
Nastoupil, Jain, Feng 2020; 38
Yang, Shaffer, Emre 2012; 21
Morschhauser, Feugier, Flinn 2021; 137
Sun, Ellerman, Mathieu 2015; 7
Abramson, Palomba, Gordon 2020; 396
Davids, Roberts, Seymour 2017; 35
Vitolo, Trneny, Belada 2017; 35
Zitvogel, Kroemer 2012; 1
Crump, Kuruvilla, Couban 2014; 32
Caimi, Ai, Alderuccio 2021; 22
Fenske, Ahn, Graff 2016; 174
Goebeler, Knop, Viardot 2016; 34
Pfreundschuh, Schubert, Ziepert 2008; 9
Engelberts, Hiemstra, de Jong 2020; 52
Wilson, Young, Schmitz 2015; 21
Tan, Bedard, Kuruvilla 2014; 4
Kantarjian, Stein, Gokbuget 2017; 376
Nowakowski, Chiappella, Gascoyne 2021; 39
van Kampen, Canals, Schouten 2011; 29
Locke, Miklos, Jacobson 2022; 386
Salles, Duell, Gonzalez Barca 2020; 21
Phelan, Young, Webster 2018; 560
Morschhauser, Flinn, Advani 2019; 6
Alizadeh, Eisen, Davis 2000; 403
Pfreundschuh, Trumper, Osterborg 2006; 7
Iqbal, Sanger, Horsman 2004; 165
Robinson, Boumendil, Finel 2016; 51
Senter, Sievers 2012; 30
Ribrag, Morschhauser, McKay 2018; 132
Chapuy, Stewart, Dunford 2018; 24
El Gnaoui, Dupuis, Belhadj 2007; 18
LeBlanc, Hideshima, Catley 2004; 103
Hutchings, Mous, Clausen 2021; 398
Nowakowski, LaPlant, Macon 2015; 33
McDaniel, Pinilla-Ibarz, Epling-Burnette 2012; 2012
Gokbuget, Zugmaier, Klinger 2017; 102
Erdmann, Klener, Lynch 2017; 130
Ohmachi, Niitsu, Uchida 2013; 31
Zhu, Corral, Fleming 2008; 57
bibr49-20406207221103321
bibr77-20406207221103321
bibr64-20406207221103321
bibr51-20406207221103321
bibr91-20406207221103321
bibr92-20406207221103321
bibr24-20406207221103321
bibr11-20406207221103321
bibr48-20406207221103321
bibr78-20406207221103321
bibr52-20406207221103321
bibr62-20406207221103321
bibr12-20406207221103321
bibr22-20406207221103321
bibr63-20406207221103321
bibr89-20406207221103321
bibr79-20406207221103321
bibr93-20406207221103321
bibr19-20406207221103321
bibr23-20406207221103321
bibr9-20406207221103321
bibr13-20406207221103321
bibr39-20406207221103321
bibr59-20406207221103321
bibr87-20406207221103321
bibr67-20406207221103321
bibr47-20406207221103321
bibr82-20406207221103321
bibr8-20406207221103321
bibr95-20406207221103321
bibr55-20406207221103321
bibr75-20406207221103321
bibr35-20406207221103321
bibr65-20406207221103321
bibr45-20406207221103321
bibr25-20406207221103321
bibr27-20406207221103321
bibr17-20406207221103321
bibr37-20406207221103321
bibr20-20406207221103321
bibr80-20406207221103321
bibr10-20406207221103321
bibr60-20406207221103321
bibr90-20406207221103321
bibr30-20406207221103321
bibr40-20406207221103321
bibr70-20406207221103321
bibr6-20406207221103321
bibr50-20406207221103321
bibr71-20406207221103321
bibr97-20406207221103321
bibr29-20406207221103321
bibr57-20406207221103321
bibr84-20406207221103321
bibr5-20406207221103321
bibr44-20406207221103321
bibr15-20406207221103321
bibr31-20406207221103321
bibr28-20406207221103321
bibr72-20406207221103321
bibr85-20406207221103321
bibr98-20406207221103321
bibr42-20406207221103321
bibr32-20406207221103321
bibr68-20406207221103321
bibr4-20406207221103321
bibr58-20406207221103321
bibr99-20406207221103321
Jacobson C (bibr53-20406207221103321) 2020; 136
bibr73-20406207221103321
bibr69-20406207221103321
bibr83-20406207221103321
bibr3-20406207221103321
bibr43-20406207221103321
bibr33-20406207221103321
bibr26-20406207221103321
bibr61-20406207221103321
bibr41-20406207221103321
bibr54-20406207221103321
Kamdar MK (bibr18-20406207221103321) 2021; 138
bibr74-20406207221103321
bibr81-20406207221103321
bibr94-20406207221103321
bibr2-20406207221103321
bibr34-20406207221103321
bibr14-20406207221103321
bibr21-20406207221103321
bibr38-20406207221103321
bibr88-20406207221103321
bibr7-20406207221103321
Swerdlow SC (bibr1-20406207221103321) 2017
bibr76-20406207221103321
bibr66-20406207221103321
bibr96-20406207221103321
bibr86-20406207221103321
bibr46-20406207221103321
bibr56-20406207221103321
bibr36-20406207221103321
bibr16-20406207221103321
References_xml – volume: 37
  start-page: 481
  year: 2019
  end-page: 489
  article-title: Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study
  publication-title: J Clin Oncol
– volume: 138
  start-page: 91
  year: 2021
  article-title: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) As second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study
  publication-title: Blood
– volume: 57
  start-page: 1849
  year: 2008
  end-page: 1859
  article-title: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
  publication-title: Cancer Immunol Immunother
– volume: 26
  start-page: 111
  year: 2005
  end-page: 117
  article-title: Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
  publication-title: Trends Immunol
– volume: 403
  start-page: 503
  year: 2000
  end-page: 511
  article-title: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
  publication-title: Nature
– volume: 130
  start-page: 310
  year: 2017
  end-page: 322
  article-title: Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
  publication-title: Blood
– volume: 30
  start-page: 631
  year: 2012
  end-page: 637
  article-title: The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
  publication-title: Nat Biotechnol
– volume: 39
  year: 2021
  article-title: First results of DLBCL patients treated with CAR T-cells and enrolled in DESCAR-T registry, a French real-life database for CAR T-cells in hematologic malagnancies
  publication-title: Hematol Oncol
– volume: 35
  start-page: 826
  year: 2017
  end-page: 833
  article-title: Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma
  publication-title: J Clin Oncol
– volume: 1
  start-page: 1223
  year: 2012
  end-page: 1225
  article-title: Targeting PD-1/PD-L1 interactions for cancer immunotherapy
  publication-title: Oncoimmunology
– volume: 23
  start-page: 677
  year: 2013
  end-page: 692
  article-title: EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
  publication-title: Cancer Cell
– volume: 35
  start-page: 1803
  year: 2017
  end-page: 1813
  article-title: Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels
  publication-title: J Clin Oncol
– volume: 376
  start-page: 836
  year: 2017
  end-page: 847
  article-title: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
  publication-title: N Engl J Med
– volume: 136
  year: 2020 1196
  article-title: Outcomes of treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) in the nonuniversity setting: initial results from the Outreach Study
  publication-title: Blood
– volume: 18
  start-page: 1363
  year: 2007
  end-page: 1368
  article-title: Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
  publication-title: Ann Oncol
– volume: 380
  start-page: 45
  year: 2019
  end-page: 56
  article-title: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
  publication-title: N Engl J Med
– volume: 174
  start-page: 235
  year: 2016
  end-page: 248
  article-title: Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation
  publication-title: Br J Haematol
– volume: 386
  start-page: 640
  year: 2022
  end-page: 654
  article-title: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
  publication-title: N Engl J Med
– volume: 91
  start-page: 931
  year: 2012
  end-page: 939
  article-title: Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study
  publication-title: Ann Hematol
– volume: 38
  start-page: 155
  year: 2020
  end-page: 165
  article-title: Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
  publication-title: J Clin Oncol
– volume: 4
  start-page: 6157
  year: 2020
  end-page: 6168
  article-title: CAR T-cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison
  publication-title: Blood Adv
– volume: 34
  start-page: 1104
  year: 2016
  end-page: 1111
  article-title: Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study
  publication-title: J Clin Oncol
– volume: 39
  year: 2021
  article-title: Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
  publication-title: Cancer Cell
– volume: 12
  start-page: 63
  year: 2015
  article-title: Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer
  publication-title: Nat Rev Clin Oncol
– volume: 21
  start-page: 978
  year: 2020
  end-page: 988
  article-title: Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
  publication-title: Lancet Oncol
– volume: 21
  start-page: 723
  year: 2012
  end-page: 737
  article-title: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
  publication-title: Cancer Cell
– volume: 7
  start-page: 379
  year: 2006
  end-page: 391
  article-title: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
  publication-title: Lancet Oncol
– volume: 372
  start-page: 311
  year: 2015
  end-page: 319
  article-title: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma
  publication-title: N Engl J Med
– volume: 37
  year: 2020
  article-title: A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
  publication-title: Cancer Cell
– volume: 378
  start-page: 1396
  year: 2018
  end-page: 1407
  article-title: Genetics and pathogenesis of diffuse large B-cell lymphoma
  publication-title: N Engl J Med
– volume: 39
  start-page: 1317
  year: 2021
  end-page: 1328
  article-title: ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma
  publication-title: J Clin Oncol
– volume: 106
  start-page: 2417
  year: 2021
  end-page: 2426
  article-title: Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
  publication-title: Haematologica
– volume: 131
  start-page: 1094
  year: 2018
  end-page: 1105
  article-title: ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
  publication-title: Blood
– volume: 21
  start-page: 1746
  year: 2015
  end-page: 1753
  article-title: The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen
  publication-title: Biol Blood Marrow Transplant
– volume: 379
  start-page: 1711
  year: 2018
  end-page: 1721
  article-title: CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma
  publication-title: N Engl J Med
– volume: 386
  start-page: 692
  year: 2022
  end-page: 696
  article-title: CAR T-cell therapy for large B–cell lymphoma – who, when, and how?
  publication-title: N Engl J Med
– volume: 29
  start-page: 1342
  year: 2011
  end-page: 1348
  article-title: Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry
  publication-title: J Clin Oncol
– volume: 26
  start-page: S41
  year: 2020
  end-page: S42
  article-title: A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas
  publication-title: Biol Blood Marrow Transplant
– volume: 7
  year: 2015
  article-title: Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
  publication-title: Sci Transl Med
– volume: 52
  start-page: 102625
  year: 2020
  article-title: DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
  publication-title: EBioMedicine
– volume: 114
  start-page: 2721
  year: 2009
  end-page: 2729
  article-title: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
  publication-title: Blood
– volume: 24
  start-page: 679
  year: 2018
  end-page: 690
  article-title: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
  publication-title: Nat Med
– volume: 32
  start-page: 3490
  year: 2014
  end-page: 3496
  article-title: Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12
  publication-title: J Clin Oncol
– volume: 105
  start-page: 13520
  year: 2008
  end-page: 13525
  article-title: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
  publication-title: Proc Natl Acad Sci USA
– volume: 134
  start-page: 6
  year: 2019
  article-title: Mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines
  publication-title: Blood
– volume: 134
  start-page: 1024
  year: 2019
  end-page: 1036
  article-title: Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
  publication-title: Blood
– volume: 15
  start-page: 757
  year: 2014
  end-page: 766
  article-title: Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
  publication-title: Lancet Oncol
– volume: 98
  start-page: 1726
  year: 2013
  end-page: 1731
  article-title: Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study association trial
  publication-title: Haematologica
– volume: 6
  start-page: e254
  year: 2019
  end-page: e265
  article-title: Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
  publication-title: Lancet Haematol
– volume: 31
  start-page: 2103
  year: 2013
  end-page: 2109
  article-title: Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
  publication-title: J Clin Oncol
– volume: 377
  start-page: 2531
  year: 2017
  end-page: 2544
  article-title: Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
  publication-title: N Engl J Med
– volume: 39
  start-page: 113
  year: 2021
  end-page: 116
  article-title: Bispecific antibodies for the treatment of lymphomas: promises and challenges
  publication-title: Hematol Oncol
– volume: 22
  start-page: 790
  year: 2021
  end-page: 800
  article-title: Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
  publication-title: Lancet Oncol
– volume: 271
  start-page: 822
  year: 1996
  end-page: 825
  article-title: Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases
  publication-title: Science
– volume: 3
  start-page: 2491
  year: 2019
  end-page: 2498
  article-title: Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
  publication-title: Blood Adv
– volume: 27
  start-page: 466
  year: 2015
  end-page: 474
  article-title: Smart CARs engineered for cancer immunotherapy
  publication-title: Curr Opin Oncol
– volume: 130
  start-page: 1800
  year: 2017
  end-page: 1808
  article-title: Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
  publication-title: Blood
– volume: 116
  start-page: 3227
  year: 2010
  end-page: 3237
  article-title: Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
  publication-title: Blood
– volume: 3
  start-page: 360
  year: 2019
  end-page: 369
  article-title: PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL
  publication-title: Blood Adv
– volume: 463
  start-page: 88
  year: 2010
  end-page: 92
  article-title: Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
  publication-title: Nature
– volume: 165
  start-page: 159
  year: 2004
  end-page: 166
  article-title: BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
  publication-title: Am J Pathol
– volume: 9
  start-page: 105
  year: 2008
  end-page: 116
  article-title: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
  publication-title: Lancet Oncol
– volume: 35
  start-page: 3529
  year: 2017
  end-page: 3537
  article-title: Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma
  publication-title: J Clin Oncol
– volume: 62
  start-page: 3098
  year: 2021
  end-page: 3108
  article-title: Glofitamab CD20-TCB bispecific antibody
  publication-title: Leuk Lymphoma
– volume: 396
  start-page: 1885
  year: 2020
  end-page: 1894
  article-title: Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
  publication-title: Lancet
– volume: 102
  start-page: e132
  year: 2017
  end-page: e135
  article-title: Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia
  publication-title: Haematologica
– volume: 22
  start-page: 1403
  year: 2021
  end-page: 1415
  article-title: Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
  publication-title: Lancet Oncol
– volume: 560
  start-page: 387
  year: 2018
  end-page: 391
  article-title: A multiprotein supercomplex controlling oncogenic signalling in lymphoma
  publication-title: Nature
– volume: 34
  start-page: 2184
  year: 2020
  end-page: 2197
  article-title: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
  publication-title: Leukemia
– volume: 127
  start-page: 1410
  year: 2016
  end-page: 1416
  article-title: Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
  publication-title: Blood
– volume: 28
  start-page: 4184
  year: 2010
  end-page: 4190
  article-title: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
  publication-title: J Clin Oncol
– volume: 33
  start-page: 251
  year: 2015
  end-page: 257
  article-title: Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study
  publication-title: J Clin Oncol
– volume: 103
  start-page: 1787
  year: 2004
  end-page: 1790
  article-title: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
  publication-title: Blood
– volume: 37
  start-page: 1285
  year: 2019
  end-page: 1295
  article-title: Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma
  publication-title: J Clin Oncol
– volume: 386
  start-page: 629
  year: 2022
  end-page: 639
  article-title: Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma
  publication-title: N Engl J Med
– volume: 136
  start-page: 40
  year: 2020
  end-page: 42
  article-title: Long-term survival and gradual recovery of B cells in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel)
  publication-title: Blood
– volume: 23
  start-page: 4127
  year: 2017
  end-page: 4137
  article-title: A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma
  publication-title: Clin Cancer Res
– volume: 7
  start-page: e511
  year: 2020
  end-page: e522
  article-title: Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
  publication-title: Lancet Haematol
– volume: 38
  start-page: 3119
  year: 2020
  end-page: 3128
  article-title: Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
  publication-title: J Clin Oncol
– volume: 346
  start-page: 235
  year: 2002
  end-page: 242
  article-title: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
  publication-title: N Engl J Med
– volume: 346
  start-page: 1937
  year: 2002
  end-page: 1947
  article-title: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
  publication-title: N Engl J Med
– volume: 13
  start-page: 1250
  year: 2012
  end-page: 1259
  article-title: Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
  publication-title: Lancet Oncol
– volume: 398
  start-page: 1157
  year: 2021
  end-page: 1169
  article-title: Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
  publication-title: Lancet
– volume: 21
  start-page: 922
  year: 2015
  end-page: 926
  article-title: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
  publication-title: Nat Med
– volume: 101
  start-page: e385
  year: 2016
  end-page: e386
  article-title: Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab
  publication-title: Haematologica
– volume: 20
  start-page: 649
  year: 2019
  end-page: 662
  article-title: Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
  publication-title: Lancet Oncol
– volume: 39
  start-page: 1959
  year: 2021
  end-page: 1970
  article-title: Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
  publication-title: J Clin Oncol
– volume: 386
  start-page: 351
  year: 2022
  end-page: 363
  article-title: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
  publication-title: N Engl J Med
– volume: 100
  start-page: 9991
  year: 2003
  end-page: 9996
  article-title: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
  publication-title: Proc Natl Acad Sci USA
– volume: 396
  start-page: 839
  year: 2020
  end-page: 852
  article-title: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
  publication-title: Lancet
– volume: 26
  start-page: 677
  year: 2008
  end-page: 704
  article-title: PD-1 and its ligands in tolerance and immunity
  publication-title: Annu Rev Immunol
– volume: 137
  start-page: 600
  year: 2021
  end-page: 609
  article-title: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
  publication-title: Blood
– volume: 4
  start-page: 527
  year: 2014
  end-page: 537
  article-title: Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy
  publication-title: Cancer Discov
– volume: 132
  start-page: 4196
  year: 2018
  article-title: Interim results from an ongoing phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
  publication-title: Blood
– volume: 51
  start-page: 365
  year: 2016
  end-page: 371
  article-title: Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
  publication-title: Bone Marrow Transplant
– volume: 2012
  start-page: 513702
  year: 2012
  article-title: Molecular action of lenalidomide in lymphocytes and hematologic malignancies
  publication-title: Adv Hematol
– volume: 12
  start-page: 1013
  year: 2011
  end-page: 1022
  article-title: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
  publication-title: Lancet Oncol
– ident: bibr8-20406207221103321
  doi: 10.1200/JCO.20.01366
– ident: bibr90-20406207221103321
  doi: 10.3324/haematol.2016.147256
– ident: bibr34-20406207221103321
  doi: 10.1182/blood-2019-123742
– ident: bibr78-20406207221103321
  doi: 10.1146/annurev.immunol.26.021607.090331
– ident: bibr47-20406207221103321
  doi: 10.1016/S2352-3026(19)30026-2
– ident: bibr62-20406207221103321
  doi: 10.1016/j.bbmt.2015.05.010
– ident: bibr83-20406207221103321
  doi: 10.1038/s41586-018-0290-0
– ident: bibr70-20406207221103321
  doi: 10.3324/haematol.2016.153957
– ident: bibr61-20406207221103321
  doi: 10.1200/JCO.2010.30.2596
– ident: bibr14-20406207221103321
  doi: 10.1200/JCO.2010.28.1618
– ident: bibr28-20406207221103321
  doi: 10.1200/JCO.19.00172
– ident: bibr76-20406207221103321
  doi: 10.4161/onci.21335
– ident: bibr88-20406207221103321
  doi: 10.1007/s00262-008-0512-7
– ident: bibr24-20406207221103321
  doi: 10.1016/S1470-2045(12)70481-3
– ident: bibr45-20406207221103321
  doi: 10.1038/nbt.2289
– ident: bibr75-20406207221103321
  doi: 10.1016/j.ebiom.2019.102625
– ident: bibr9-20406207221103321
  doi: 10.1016/S1470-2045(18)30935-5
– ident: bibr63-20406207221103321
  doi: 10.1182/bloodadvances.2018027748
– volume: 138
  start-page: 91
  year: 2021
  ident: bibr18-20406207221103321
  publication-title: Blood
  doi: 10.1182/blood-2021-147913
– ident: bibr96-20406207221103321
  doi: 10.1016/j.ccr.2013.04.011
– ident: bibr86-20406207221103321
  doi: 10.1182/blood-2003-02-0361
– ident: bibr93-20406207221103321
  doi: 10.1016/S0002-9440(10)63284-1
– ident: bibr94-20406207221103321
  doi: 10.1073/pnas.0804295105
– ident: bibr33-20406207221103321
  doi: 10.1182/blood-2015-06-651380
– ident: bibr57-20406207221103321
  doi: 10.1002/hon.84_2879
– ident: bibr80-20406207221103321
  doi: 10.1056/NEJMoa012914
– ident: bibr37-20406207221103321
  doi: 10.1200/JCO.18.00766
– ident: bibr23-20406207221103321
  doi: 10.1016/S1470-2045(08)70002-0
– ident: bibr31-20406207221103321
  doi: 10.1056/NEJMoa1804980
– ident: bibr38-20406207221103321
  doi: 10.1056/NEJMoa1807315
– ident: bibr56-20406207221103321
  doi: 10.1016/j.bbmt.2019.12.108
– ident: bibr49-20406207221103321
  doi: 10.1097/CCO.0000000000000232
– ident: bibr50-20406207221103321
  doi: 10.1016/S0140-6736(20)32334-5
– ident: bibr85-20406207221103321
  doi: 10.1155/2012/513702
– ident: bibr12-20406207221103321
  doi: 10.1056/NEJMoa2115304
– ident: bibr6-20406207221103321
  doi: 10.1016/j.ccell.2020.03.015
– ident: bibr15-20406207221103321
  doi: 10.1200/JCO.2013.53.9593
– ident: bibr60-20406207221103321
  doi: 10.1111/bjh.14046
– ident: bibr52-20406207221103321
  doi: 10.1200/JCO.2016.71.3024
– ident: bibr84-20406207221103321
  doi: 10.1016/j.ccell.2021.10.006
– ident: bibr35-20406207221103321
  doi: 10.1200/JCO.20.03175
– ident: bibr66-20406207221103321
  doi: 10.1016/S1470-2045(14)70161-5
– ident: bibr69-20406207221103321
  doi: 10.1056/NEJMoa1609783
– ident: bibr39-20406207221103321
  doi: 10.1038/nm.3884
– ident: bibr7-20406207221103321
  doi: 10.1200/JCO.18.02403
– ident: bibr32-20406207221103321
  doi: 10.1016/S0140-6736(20)31366-0
– ident: bibr64-20406207221103321
  doi: 10.1007/s00277-011-1395-9
– ident: bibr25-20406207221103321
  doi: 10.1200/JCO.2017.73.3402
– ident: bibr95-20406207221103321
  doi: 10.1182/blood.2020006578
– ident: bibr20-20406207221103321
  doi: 10.1093/annonc/mdm133
– ident: bibr72-20406207221103321
  doi: 10.1182/bloodadvances.2019000025
– ident: bibr59-20406207221103321
  doi: 10.1056/NEJMe2118899
– volume-title: WHO classification of tumours of haematopoietic and lymphoid tissues
  year: 2017
  ident: bibr1-20406207221103321
– ident: bibr67-20406207221103321
  doi: 10.1182/bloodadvances.2020003036
– ident: bibr36-20406207221103321
  doi: 10.1016/S0140-6736(21)00889-8
– ident: bibr19-20406207221103321
  doi: 10.1200/JCO.2012.46.5203
– ident: bibr11-20406207221103321
  doi: 10.1016/S1470-2045(06)70664-7
– ident: bibr98-20406207221103321
  doi: 10.1182/blood.2018891598
– ident: bibr4-20406207221103321
  doi: 10.1038/s41591-018-0016-8
– ident: bibr74-20406207221103321
  doi: 10.1080/10428194.2021.1953016
– ident: bibr16-20406207221103321
  doi: 10.1056/NEJMoa2116133
– ident: bibr44-20406207221103321
  doi: 10.1016/S2352-3026(20)30120-4
– ident: bibr68-20406207221103321
  doi: 10.1002/hon.2858
– ident: bibr17-20406207221103321
  doi: 10.1056/NEJMoa2116596
– ident: bibr26-20406207221103321
  doi: 10.1016/S1470-2045(20)30225-4
– ident: bibr97-20406207221103321
  doi: 10.1158/2159-8290.CD-13-1005
– ident: bibr46-20406207221103321
  doi: 10.1182/blood-2009-02-205500
– ident: bibr55-20406207221103321
  doi: 10.1200/JCO.19.02104
– ident: bibr77-20406207221103321
  doi: 10.1038/nrclinonc.2014.221
– ident: bibr22-20406207221103321
  doi: 10.1016/S1470-2045(11)70235-2
– ident: bibr10-20406207221103321
  doi: 10.1056/NEJMoa011795
– ident: bibr51-20406207221103321
  doi: 10.1016/j.it.2004.12.003
– ident: bibr54-20406207221103321
  doi: 10.1016/S1470-2045(21)00375-2
– ident: bibr73-20406207221103321
  doi: 10.1126/scitranslmed.aaa4802
– ident: bibr99-20406207221103321
  doi: 10.1002/hon.145_2630
– ident: bibr65-20406207221103321
  doi: 10.1038/bmt.2015.286
– ident: bibr2-20406207221103321
  doi: 10.1038/35000501
– ident: bibr58-20406207221103321
  doi: 10.1182/blood-2020-136640
– ident: bibr27-20406207221103321
  doi: 10.3324/haematol.2020.275958
– ident: bibr48-20406207221103321
  doi: 10.1182/blood-2017-10-813493
– ident: bibr92-20406207221103321
  doi: 10.1182/blood-2016-12-758599
– ident: bibr91-20406207221103321
  doi: 10.1200/JCO.2014.55.5714
– ident: bibr82-20406207221103321
  doi: 10.1126/science.271.5250.822
– ident: bibr40-20406207221103321
  doi: 10.1158/1078-0432.CCR-16-2818
– ident: bibr30-20406207221103321
  doi: 10.1056/NEJMoa1707447
– ident: bibr71-20406207221103321
  doi: 10.1200/JCO.2014.59.1586
– ident: bibr5-20406207221103321
  doi: 10.1056/NEJMoa1801445
– ident: bibr42-20406207221103321
  doi: 10.1200/JCO.2016.70.4320
– ident: bibr13-20406207221103321
  doi: 10.1182/blood-2017-03-769620
– ident: bibr89-20406207221103321
  doi: 10.1016/j.ccr.2012.05.024
– volume: 136
  start-page: 40
  year: 2020
  ident: bibr53-20406207221103321
  publication-title: Blood
– ident: bibr21-20406207221103321
  doi: 10.3324/haematol.2013.090597
– ident: bibr41-20406207221103321
  doi: 10.1038/s41375-020-0743-y
– ident: bibr87-20406207221103321
  doi: 10.1182/blood-2010-04-279893
– ident: bibr81-20406207221103321
  doi: 10.1038/nature08638
– ident: bibr79-20406207221103321
  doi: 10.1056/NEJMoa1411087
– ident: bibr29-20406207221103321
  doi: 10.1016/S1470-2045(21)00139-X
– ident: bibr43-20406207221103321
  doi: 10.1182/blood-2018-99-113411
– ident: bibr3-20406207221103321
  doi: 10.1073/pnas.1732008100
SSID ssj0000463345
Score 2.3134415
SecondaryResourceType review_article
Snippet Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of...
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60-65% of...
Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of aggressive lymphoma. Depending on individual risk factors, roughly 60–65% of...
SourceID doaj
pubmedcentral
proquest
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 20406207221103321
SubjectTerms Chemotherapy
Immunotherapy
Lymphoma
Monoclonal antibodies
Review
Stem cell transplantation
Targeted cancer therapy
Transplants & implants
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9BL6ZNuk5YpFAoFE1sPSzo2JSEU0lMDuZmRLdPA1l7i3UPon--MrWzWLUkvvVoSkjUj6Rtp5hshPuhoVB0dZkpakxGkDhla77LWkoY0ztrWcHDy-bfy7EJ_vTSXO6m-2CdsogeeJu4ouiB1tA7LGLUPwcmG7G7UrZeNbqfdN_f5jjE17sG6VEqb9IzJDEuStLWUuZVs8Sgli9lBNPL1z0Dmny6SO35e49Fz-lQ8SZgRPk9jfSYexe652D9Pr-IvxK9EsgT95KEC2DUwkYXA6i6YcoCrDgjvwda5HPoWErHqAHwjCxzashpic0TjvR5T8dwA51DZDBGW7DQOxxnf9cPyhtSg_4kvxcXpyfcvZ1lKqpDVhD3WmTU-FsFjS3agN9pi4YNWEkPZxGAJLUUMua0lIUOyTAwaFfIga5S-zWOLhXol9rq-i68FYGmpCeEJSaYtehKUVL52PrimNGjdQuS3M1zViXGcE18sqyKRjP8llIX4tG2ymug2Hqp8zGLbVmSm7PED6U-V9Kf6l_4sxOGt0Ku0fIdKshVl6SCnPt5vi2nh8QxjF_sN1Smd4R3R-4WwM2WZDWhe0l39GCm8yepVxlPnH1mt7jq-91_f_I9_PRCPJUdvjJdIh2Jvfb2JbwlTrcO7cfn8BsgUG-0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA-1BfFFtCqutpKCIAihu_nYJE9ii6UI7VML97Yku1ktnLvn7d1D8Z93JpfbcxX7mg-SzUyyv5lMfkPIexmUqINxTHCtGEBqz5y2hrUaNKQxWrcKHydfXZeXt_LrTM2Sw21IYZXbMzEe1E1fo4_8lCOw1XC2Fp8WPxlmjcLb1ZRC4xE5KACJYOoGPdOjjwXZsETMU8wxcK7kuU4Xm8i5hGVYxNEGEoIXk19TZPCfwM6_gyb_iPyKP6OLZ-RpQpH080bsz8le6A7J46t0T_6C_Eq0S7TfxKxQ1zV0Qx9CF7vnlQO96yggQDqGm9O-pYlqdaDoo6X42GUxhOYU5ruMyXnuKWZVWQ-BzjGMnJ4x9P7T-T0oRv_DvSS3F19uzi9ZSrPAakAjK6aVDYW3rgXL0CqpXWG9FNz5sgleA34Kzue65oAVwVZRTgmfe147bts8tK4Qr8h-13fhNaGu1NAFEAYHY9dZ4wF82NpYb5pSOW0ykm9XuKoTBzmmwphXRaId_0coGfk4dllsCDgeanyGYhsbInd2LOiX36q0FasA05JBG1eGIK33hjeFlU62ljeyLXlGjrZCr9KGHqqd-mXkZKyGrYgr7LrQr6FNaRSekdZmRE-UZTKhaU139z2SeoMdLJSFwT-gWu0G_u-3vnl4mm_JE44vNaLD6Ijsr5brcAz4aeXfxU3yG2s-FKo
  priority: 102
  providerName: ProQuest
Title Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma
URI https://journals.sagepub.com/doi/full/10.1177/20406207221103321
https://www.proquest.com/docview/2758570671
https://www.proquest.com/docview/2685031899
https://pubmed.ncbi.nlm.nih.gov/PMC9243592
https://doaj.org/article/e8b24e78a6ee49bb82d194a4f92d4f62
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9swFBa9wNjL2JVl64IGg8FAqy1blvQ0mtFQBi2jtCxvRrLlrZDYIY4fQv98z7Fld96NPQVsmaNIR_Z3bt8h5F3sRJQ5ZVjEpWAAqS0zUitWSNCQXElZCCxOPr9Izq7jLwux2CNVXwvjV7D-iGlVMKP2ZY2nG73Rxz7ICBY7fId4IDmaL1HEw0_NdpV27u6-qwZewfh0s8LQdoYJkTvWl7ftk0OkLocjcXgyv_x2NbhlkEAralsbowyGQnws9I9yR1-zlvR_hFR_zbP8KVms_X7NH5NHHnjSk05TnpA9Vz4lD859aP0ZufVMTbTq0lyoKXPaMY7Q9X1FZk1vSgqgkQ4Z6rQqqGdnrSm6dSnWx6xrlx_DfDdtP58dxUYsTe3oEjPP6YxhwIAud6BL1co8J9fz06vPZ8x3ZmAZAJgtk0K70GpTgDGpRSxNqG0ccWOT3FkJkMsZG8iMA7wE80YYEdnA8sxwXQSuMGH0ghyUVeleEmoSCY8AKOFgHxutLOAVnSltVZ4II9WEBP0Kp5mnLcfuGcs09Ezlv23KhHwYHll3nB3_GjzDbRsGIt12e6HafE_96U0dTCt2UpnEuVhbq3ge6tjEheZ5XCR8Qo76TU97DU45mmIS0ADIeDvchtOLK2xKVzUwJlECX6taT4gcKctoQuM75c2PlgccTOdIaBD-HtXqXvBf_-ur_x75mjzkWOfRupuOyMF207g3gL62dkr25UJO_bmB39npxdfLaevLuAPkNSt4
linkProvider SAGE Publications
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTgJeED9FxgAjgZCQoiVOHMcPE6KwqWNrhdAm7S3YiQOTuqQ0rVDF_8bfxl3qphTE3vbqOImTs8_fne--A3gZWxHlNtV-xKXwEVIbX0uV-qXEGVKkUpaCkpOHo2RwFn88F-db8GuVC0NhlSud2Crqos7JR77HCdhK1K3h28l3n6pG0enqqoSGdqUViv2WYswldhzbxQ804Zr9ow8o71ecHx6cvh_4rsqAn-NmPPOlUDY0SpdoGCkRSx0qE0dcm6SwRiJ8sNoEMucIlRCqCy0iExiea67KwJY6jPC5N2A7JgdKD7b7B6NPnzsvD_FxRW2lZE6hewkPpDtaJdYnaqMmTlZYFPFwY3NsawhsAN-_wzb_iD1rt8PDu3DH4Vj2bjnx7sGWre7DzaE7qX8APx3xE6uXUTNMVwVbEpiwyTrBs2EXFUMMyrqAd1aXzJG9Noy8xIzSbSaNLfZwvNO2PNCCUV2XeWPZmALZWd-n8wc2XuDUrC_1Qzi7FhE8gl5VV_YxMJ1IvAUxDkdzW6vUIPxReapMWiRCy9SDYPWHs9yxoFMxjnEWOuLzf4TiwZvulsmSAuSqzn0SW9eR2Lvbhnr6NXPKILM4rNjKVCfWxsqYlBehinVcKl7EZcI92F0JPXMqpcnWC8CDF91lVAb0h3Vl6zn2SVJBWlopD-TGZNkY0OaV6uJbSyuOlngkFL78NU2r9Yv_-607Vw_zOdwanA5PspOj0fETuM0pb6R1X-1Cbzad26eI5mbmmVsyDL5c9yr9DZqxV9o
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbQVqq4IJ5ioYCRkJCQTBM_YvvYAqvyaIVQK3qL7MSGSkuy2uweKv48M1lvSniJa2zHjj2OvxnPfEPIMxmUqIJxTHCtGEBqz5y2hkUNElIbraPC4OTjk-LoTL47V-fJ4IaxMGkGu5foVgUj6n_WuLsXddxPd4ygsMMxxDPNUXsRAuPId0CtMdmE7BzMPn0-HawsyIcl-kzF2IZho3S1-cf3jA6nnsN_BDx_dZv8yferP45mN8mNhCPpwWbhb5FroblNdo_TTfkd8j0RL9F247VCXVPTDYEIXVwFWHb0oqGAAengcE7bSBPZakfRSksx3GXRhXofxrvs0_NcUsyrsu4CnaMjOT1kaP-n80sQjfabu0vOZm9OXx2xlGiBVYBHVkwrG3JvXYRJtEpql1svBXe-qIPXgKCC85muOKBF0FaUU8JnnleO25iF6HJxj0yatgn3CXWFhiaAMTiou84aD_DDVsZ6UxfKaTMl2XaGyyqxkGMyjHmZJ-Lx3xZlSl4MTRYbCo5_VT7EZRsqInt2_6BdfinTZiwDDEsGbVwRgrTeG17nVjoZLa9lLPiU7G0XvdwKZMlRs9JwuEMfT4di2Iw4w64J7RrqFEbhX9LaKdEjYRkNaFzSXHztab1BExbKQufPUayuOv7rtz7475pPyO7H17Pyw9uT9w_JdY4RHL0haY9MVst1eAS4auUfp83zAzRmFn8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+options+and+future+perspectives+in+the+treatment+of+patients+with+relapsed%2Frefractory+diffuse+large+B-cell+lymphoma&rft.jtitle=Therapeutic+advances+in+hematology&rft.au=Frontzek%2C+Fabian&rft.au=Karsten%2C+Imke&rft.au=Schmitz%2C+Norbert&rft.au=Lenz%2C+Georg&rft.date=2022-06-01&rft.issn=2040-6207&rft.eissn=2040-6215&rft.volume=13&rft_id=info:doi/10.1177%2F20406207221103321&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_20406207221103321
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2040-6207&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2040-6207&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2040-6207&client=summon